Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Remifentanil as an intubating adjunct: A meta-analysis

FY 2021-22

Summary
Intubation is a procedure commonly used during general anesthesia to control patients airways and breathing. The process of intubation requires muscle paralysis to prevent vocal cord movement and coughing during tube placement. Current paralytic agents used to achieve these effects have many considerations, as they can cause significant muscle pains, anaphylaxis, and cardiac arrest. As such, many patients are not candidates for these paralytic agents, and an alternative modality for optimizing intubation is necessary for these cases. Opioids have a lengthy history within anesthesia, as they can reduce airway reflexes to intubation and decrease pain, however, they are known to cause significant respiratory depression that extends post-operatively. Remifentanil, on the other hand, is a relatively new short acting opioid whose effects lasts less than 10 minutes, and may serve as an appropriate intubation adjunct, while reducing the concern of postoperative respiratory depression.The aim of this study is to conduct a meta-analysis to determine if remifentanil provides comparable intubating conditions and success rates as paralytic agents. Other outcome measures include determining the minimal intubating dose of remifentanil to achieve these conditions, adverse events, and patient comfort postoperatively. The results of this meta-analysis may be used to inform new guidelines regarding the use of remifentanil as an alternative and substitute for paralytic agents, determine the safety profile of remifentanil, and analyze patient satisfaction postoperatively.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
467097
Name
Santos Lucia
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Remifentanil as an intubating adjunct: A meta-analysis
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Intubation; Meta-Analysis; Paralytics; Remifentanil
Abstract
Intubation is a procedure commonly used during general anesthesia to control patients airways and breathing. The process of intubation requires muscle paralysis to prevent vocal cord movement and coughing during tube placement. Current paralytic agents used to achieve these effects have many considerations, as they can cause significant muscle pains, anaphylaxis, and cardiac arrest. As such, many patients are not candidates for these paralytic agents, and an alternative modality for optimizing intubation is necessary for these cases. Opioids have a lengthy history within anesthesia, as they can reduce airway reflexes to intubation and decrease pain, however, they are known to cause significant respiratory depression that extends post-operatively. Remifentanil, on the other hand, is a relatively new short acting opioid whose effects lasts less than 10 minutes, and may serve as an appropriate intubation adjunct, while reducing the concern of postoperative respiratory depression.The aim of this study is to conduct a meta-analysis to determine if remifentanil provides comparable intubating conditions and success rates as paralytic agents. Other outcome measures include determining the minimal intubating dose of remifentanil to achieve these conditions, adverse events, and patient comfort postoperatively. The results of this meta-analysis may be used to inform new guidelines regarding the use of remifentanil as an alternative and substitute for paralytic agents, determine the safety profile of remifentanil, and analyze patient satisfaction postoperatively.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Santos, Lucia
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~